Physician profile
Ramesh Kaul
NPI 1073563466
$2,627.99
in general payments reported to CMS, 2019-2025
24 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $139 · 2021: $600 · 2022: $656 · 2023: $397 · 2024: $409 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.68 |
| Education | $147.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $560.21 | 2019-2024 | Nucala |
| Astrazeneca Pharmaceuticals LP | $349.68 | 2019-2025 | Airsupra, Fasenra, Symbicort |
| Regeneron Healthcare Solutions, INC. | $329.98 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.14 | 2019-2025 | Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $139.83 | 2021-2023 | Glassia |
| Genzyme Corporation | $130.50 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $125.75 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $94.76 | 2022 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Amgen INC. | $76.09 | 2021-2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $66.35 | 2021-2023 | |
| United Therapeutics Corporation | $62.85 | 2021-2025 | Tyvaso |
| Pfizer INC. | $55.98 | 2022-2024 | |
| Harmony Biosciences LLC | $53.79 | 2021-2022 | |
| Verona Pharma, INC. | $35.62 | 2025 | Ohtuvayre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $20.07 | 2022 | |
| Lilly USA, LLC | $19.00 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $18.19 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $16.83 | 2023 | |
| Philips North America LLC | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $14.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.80 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.25 | 2021 | |
| Insmed, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.